Search Results

Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab.

Alpine Immune Sciences, Inc. today announced that the Company has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202).

The U.S. National Science Foundation announced a highly competitive five-year award to Battelle for the continued operations and maintenance of the National Ecological Observatory Network.

Alpine Immune Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its NEON-2 trial evaluating davoceticept.

Battelle, which manages the U.S. National Science Foundation National Ecological Observatory Network program, is now using Starlink in a pilot test to achieve improved data transmission and service as part of an ongoing initiative to leverage new and innovative technologies to improve and enhance the operations of NEON.

Neon Bloom, Inc. (OTC: NBCO), is proud to announce it has closed on the acquisition of Bazelet Health Systems, Inc.

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares o

BioNTech announced the closing of the Neon Therapeutics, Inc. acquisition through an all-stock transaction.

NGM Biopharmaceuticals, Inc. announced that it has entered into a definitive Agreement and Plan of Merger under which Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.